{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.5","value":"44.0"},{"groupId":"OG001","spread":"10.8","value":"45.2"}]}],"title":"Global Score (baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.5","value":"41.4"},{"groupId":"OG001","spread":"10.6","value":"42.0"}]}],"title":"Global Score (last observation)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.5","value":"-2.8"},{"groupId":"OG001","spread":"13.1","value":"-2.6"}]}],"title":"Global Score (change)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.9","value":"80.3"},{"groupId":"OG001","spread":"25.6","value":"74.0"}]}],"title":"Physical Functioning Score (baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.0","value":"68.9"},{"groupId":"OG001","spread":"27.4","value":"68.7"}]}],"title":"Physical Functioning Score (last observation)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.5","value":"-11.4"},{"groupId":"OG001","spread":"29.2","value":"-6.9"}]}],"title":"Physical Functioning Score (change)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.8","value":"85.4"},{"groupId":"OG001","spread":"25.0","value":"77.6"}]}],"title":"Role Functioning Score (baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.1","value":"71.0"},{"groupId":"OG001","spread":"27.1","value":"72.2"}]}],"title":"Role Functioning Score (last observation)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.2","value":"-14.1"},{"groupId":"OG001","spread":"31.0","value":"-8.0"}]}],"title":"Role Functioning Score (change)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.9","value":"83.7"},{"groupId":"OG001","spread":"19.5","value":"80.9"}]}],"title":"Emotional Functioning Score (baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.7","value":"72.6"},{"groupId":"OG001","spread":"20.7","value":"74.6"}]}],"title":"Emotional Functioning Score (last observation)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.1","value":"-10.6"},{"groupId":"OG001","spread":"22.2","value":"-8.0"}]}],"title":"Emotional Functioning Score (change)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.9","value":"90.3"},{"groupId":"OG001","spread":"16.4","value":"89.3"}]}],"title":"Cognitive Functioning Score (baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.9","value":"82.9"},{"groupId":"OG001","spread":"19.3","value":"84.2"}]}],"title":"Cognitive Functioning Score (last observation)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.8","value":"-7.2"},{"groupId":"OG001","spread":"16.9","value":"-7.5"}]}],"title":"Cognitive Functioning Score (change)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.2","value":"86.0"},{"groupId":"OG001","spread":"24.0","value":"82.3"}]}],"title":"Social Functioning Score (baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.9","value":"79.7"},{"groupId":"OG001","spread":"24.4","value":"82.6"}]}],"title":"Social Functioning Score (last observation)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.2","value":"-6.4"},{"groupId":"OG001","spread":"27.6","value":"-1.9"}]}],"title":"Social Functioning Score (change)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"description":"Participants were given the Europen Organization for Research in Cancer Therapy Quality of Life Questionnaire (EORTC QLQ), version 2.0, which consisted of 30 questions. The questionnaire evaluated global health/quality of life and incorporated five functional scales (Physical; Role; Emotional; Cognitive; Social). All of the scales ranged in score from 0 (worst) to 100 (best).","dispersionType":"Standard Deviation","groups":[{"description":"Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.","id":"OG000","title":"Peginterferon α-2b"},{"description":"Participants were observed and received no treatment","id":"OG001","title":"No Treatment"}],"paramType":"MEAN","populationDescription":"Intent-to-treat population (those who received at least one dose of study drug).\n\nThe number of participants analyzed varied depending on the number of observations available for each category.","reportingStatus":"POSTED","timeFrame":"Screening and Last Observation (up to 5 years)","title":"Quality of Life","type":"SECONDARY","unitOfMeasure":"Score on a scale"}